Evidence map›Paper›PMID 38429734›Full record

ArticleEuropean journal of medical research2024

Changes of Mycobacterium tuberculosis specific antigen-stimulated CD27

Yong Fang, Yuan Tang, Qiao-Xia Luo, Na Wang, Liang Tang, Xiao-Jun Yang, Xiao-Fang You, Yu-Chun Wang, Li Liang, Jing-Bo Zhang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Correlation Between CD38Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Yong Fang *Shanghai Clinical Research Center for infectious disease(tuberculosis), Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China.
Yuan Tang *Central Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Qiao-Xia LuoThe Third People's Hospital, Tibet Autonomous Region, Lhasa, 850030, People's Republic of China.
Na WangCentral Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Liang TangCentral Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Xiao-Jun YangCentral Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
Xiao-Fang YouDepartment of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China.
Yu-Chun WangDepartment of Radiology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China.
Li LiangShanghai Clinical Research Center for infectious disease(tuberculosis), Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China.
Jing-Bo ZhangDepartment of Occupational Disease, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China. 13585506860@163.com.
Bo SuCentral Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China. su_bo_s@hotmail.com.
Wei ShaShanghai Clinical Research Center for infectious disease(tuberculosis), Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, People's Republic of China. 13671758200@126.com.
Tongji University · CNShanghai Pulmonary Hospital · CNTibet Autonomous Region People's Hospital · CN

Funding

Clinical study on the diagnostic value and efficacy evaluation of peripheral blood flow cytometry for tuberculosis fk18008Shanghai 2020 "science and technology innovation action plan" technological innovation fund-Clinical Study on New Short-Course treatment regimens and Host-Directed Therapy for MDR-TB 20Z11900500Shanghai Clinical Research Center for infectious disease (tuberculosis) 19MC1910800Shanghai key clinical specialty construction project - Tuberculosis department Shslczdzc 03001
6 · The paper itself

Abstract

backgroundThe aim of the study was to investigate whether the expression of CD27

methodsNewly diagnosed active pulmonary TB patients, latent TB infection (LTBI) and healthy controls were enrolled from January 2021 to December 2021. PTB patients were treated by standard anti-TB regimen 2HREZ/4HR (2 months of isoniazid (H), rifampin (R), ethambutol (E), and pyrazinamide (Z) followed by 4 months of isoniazid (H) and rifampin (R)). The difference of CD27

resultsTotal 45 PTB patients, 38 LTBI cases and 43 healthy controls were enrolled. The expression of CD27

conclusionThe expression of CD27

Indexed as

Mycobacterium tuberculosisTuberculosisTuberculosis, PulmonaryAntitubercular AgentsCD4-Positive T-LymphocytesHumansIsoniazidRifampinAntitubercular AgentsIsoniazidRifampinBiomarkersCD27CD38Flow cytometryIFN-γTreatment monitoringTuberculosis

Identifiers

PMID38429734
PMCPMC10908161
OpenAlexW4392388122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.